Protective Factors and the Pathogenesis of Complications in Diabetes

Endocr Rev. 2024 Mar 4;45(2):227-252. doi: 10.1210/endrev/bnad030.

Abstract

Chronic complications of diabetes are due to myriad disorders of numerous metabolic pathways that are responsible for most of the morbidity and mortality associated with the disease. Traditionally, diabetes complications are divided into those of microvascular and macrovascular origin. We suggest revising this antiquated classification into diabetes complications of vascular, parenchymal, and hybrid (both vascular and parenchymal) tissue origin, since the profile of diabetes complications ranges from those involving only vascular tissues to those involving mostly parenchymal organs. A major paradigm shift has occurred in recent years regarding the pathogenesis of diabetes complications, in which the focus has shifted from studies on risks to those on the interplay between risk and protective factors. While risk factors are clearly important for the development of chronic complications in diabetes, recent studies have established that protective factors are equally significant in modulating the development and severity of diabetes complications. These protective responses may help explain the differential severity of complications, and even the lack of pathologies, in some tissues. Nevertheless, despite the growing number of studies on this field, comprehensive reviews on protective factors and their mechanisms of action are not available. This review thus focused on the clinical, biochemical, and molecular mechanisms that support the idea of endogenous protective factors, and their roles in the initiation and progression of chronic complications in diabetes. In addition, this review also aimed to identify the main needs of this field for future studies.

Keywords: complications-macrovascular; complications-microvascular; diabetes mellitus; type 1 diabetes; type 2 diabetes.

Publication types

  • Review

MeSH terms

  • Diabetes Mellitus* / etiology
  • Diabetes Mellitus, Type 2* / complications
  • Diabetic Angiopathies* / complications
  • Humans
  • Protective Factors
  • Risk Factors